Insmed Files Countersuit Against Tercica

Law360, New York (October 17, 2006, 12:00 AM EDT) -- A long-running battle over drugs for children with short stature took another turn Friday, when Insmed Inc. countersued rival pharmaceutical company Tercica Inc. for false advertising.

In the claim, filed with the U.S. District Court in Richmond, Va., Insmed alleged that Tercica made false and misleading statements regarding both companies’ hormone replacement drugs, which are used to treat patients with severe primary IGF-I deficiency.

“At issue are statements made by Tercica that Insmed believes are likely to mislead customers into believing that [Tercica’s drug] Increlex is...
To view the full article, register now.